Immunocore Holdings (IMCR) Aperçu de l'action
Immunocore Holdings plc, avec ses filiales, se consacre au développement et à la commercialisation de médicaments immunomodulateurs pour les patients atteints de cancer, de maladies infectieuses et de maladies auto-immunes aux États-Unis, en Europe et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 4/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour IMCR à partir de nos contrôles de risques.
IMCR Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Immunocore Holdings plc Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$30.00 |
| Plus haut sur 52 semaines | US$40.71 |
| Plus bas sur 52 semaines | US$27.56 |
| Bêta | 0.74 |
| Variation sur 1 mois | 1.63% |
| Variation sur 3 mois | -8.20% |
| Variation sur 1 an | -3.88% |
| Variation sur 3 ans | -47.06% |
| Variation sur 5 ans | -24.17% |
| Évolution depuis l'introduction en bourse | -30.56% |
Nouvelles et mises à jour récentes
Mise à jour du récit • May 19
IMCR: Future Upside Will Depend On Risky Oncology Pipeline Execution
Analysts now set Immunocore Holdings' fair value at $34, up $1 from $33. This reflects adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E after recent Street research highlighted a more cautious view on upside without clearer pipeline progress.Mise à jour du récit • Apr 25
IMCR: Pipeline Upside Will Rely On Higher Risk Oncology Programs
Analysts cut their price target on Immunocore Holdings to $33 from $48, noting that Kimmtrak provides an established revenue base in uveal melanoma. They indicated that the investment case now depends more on what they view as higher risk pipeline outcomes.Recent updates
Mise à jour du récit • May 19
IMCR: Future Upside Will Depend On Risky Oncology Pipeline Execution
Analysts now set Immunocore Holdings' fair value at $34, up $1 from $33. This reflects adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E after recent Street research highlighted a more cautious view on upside without clearer pipeline progress.Mise à jour du récit • Apr 25
IMCR: Pipeline Upside Will Rely On Higher Risk Oncology Programs
Analysts cut their price target on Immunocore Holdings to $33 from $48, noting that Kimmtrak provides an established revenue base in uveal melanoma. They indicated that the investment case now depends more on what they view as higher risk pipeline outcomes.Mise à jour du récit • Apr 08
IMCR: Pipeline Risk And Sector Rotation Will Shape Balanced 2026 Outlook
Analysts have reset their average price target on Immunocore to $33. Some frame this move as a sign that Kimmtrak's uveal melanoma revenue potential is closer to peak, with future upside hinging more on higher risk pipeline assets, while others still see room for value in the broader small to mid cap biotech group.Mise à jour du récit • Mar 24
IMCR: Sector Rotation And Pipeline Risk Will Shape Balanced 2026 Outlook
Narrative Update The analyst fair value estimate for Immunocore Holdings has shifted from $38 to $33. This change reflects mixed Street views, with some analysts highlighting Kimmtrak's moderate market and maturing sales, while others point to broader biotech sentiment and pipeline potential as key factors for future returns.Mise à jour du récit • Mar 10
IMCR: Sector Rotation And Capital Production Shift Will Shape Bullish 2026 Outlook
Analysts have nudged their fair value estimate for Immunocore Holdings up from $37.00 to $38.00, citing higher Street price targets from $40 to $55. These targets reflect growing confidence in small to mid cap biotech as some companies are seen as shifting from capital consumers to capital producers and benefiting from improving sector sentiment.
Mise à jour du récit • Feb 24
IMCR: Bullish View Will Center On 2026 Capital Producer Transition
Analysts have nudged their average price target on Immunocore higher, with recent moves such as a lift to $40 and an upgrade anchored by a new $55 target. These changes support a small upward adjustment in our modeled fair value to $66.57, alongside slightly higher discount rate and P/E assumptions.Mise à jour du récit • Feb 08
IMCR: Sector Rotation And Pipeline Execution Will Shape Bullish 2026 Outlook
Narrative Update on Immunocore Holdings Analysts have lifted their average price target for Immunocore to a range anchored by the recent US$40 and US$55 targets. This reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples as they factor in improving sentiment toward small to mid cap biotech names.Mise à jour du récit • Jan 24
IMCR: Balanced Outlook As Hepatitis B Data And Sector Rotation Shape 2026
Analysts have lifted their price target framework for Immunocore Holdings from about $24.93 to $37.00, reflecting recent Street research in which firms increased targets to as high as $55 and highlighted improving biotech fundamentals along with shifting investor attention toward small to mid cap commercial names. Analyst Commentary Recent Street research on Immunocore Holdings clusters around a common theme, with several firms linking their updated views to a broader shift in attention toward small to mid cap commercial biotech names.Mise à jour du récit • Jan 10
IMCR: Bullish View Will Center On Advancing HBV TCR Bispecific Program
Narrative Update Analysts have lifted their blended price target for Immunocore, with recent moves such as a Morgan Stanley increase to $40 and a UBS move to $55 contributing to a higher implied fair value of about $66.36, based on updated assumptions for growth, margins and a higher future P/E multiple. Analyst Commentary Recent Street research around Immunocore centers on shifting views of small to mid cap biotech, updated price targets, and how investors might think about the balance between potential upside and execution risk.Seeking Alpha • Nov 08
Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst
Summary Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentiment says to "Hold" based on slowing sales growth, but this does not factor in the broad pipeline. To me, this is a qualified "Buy" assuming they can take any one of their many projects to the finish line. Read the full article on Seeking AlphaArticle d’analyse • Aug 02
Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Jun 10
Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders have had their patience rewarded with a 27% share price jump in...Seeking Alpha • Apr 27
Immunocore Holdings: A Name On My Watch List
Summary Immunocore Holdings' shares have fallen over 60% since February 2024 due to lack of catalysts and competition for its main product, Kimmtrak. Kimmtrak, approved for metastatic uveal melanoma, faces market saturation and competition, but label expansion could significantly increase its market potential. Immunocore's pipeline includes promising early-stage oncology and infectious disease programs, but pivotal data for key trials won't be available until 2H26 or later. An analysis around Immuncore Holdings follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Apr 26
Improved Revenues Required Before Immunocore Holdings plc (NASDAQ:IMCR) Shares Find Their Feet
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right...
Nouveau récit • Mar 23
AI Tools And Global Expansion Will Broaden KIMMTRAK's Market Reach
Expansion into less dense U.S. markets and international launches are key to driving revenue growth for Immunocore's KIMMTRAK.Article d’analyse • Mar 04
Is Immunocore Holdings (NASDAQ:IMCR) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 27
Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Summary Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries inherent biotech industry risks. IMCR's financials show increased product revenue and net income, with substantial cash reserves to support ongoing and future developments. Read the full article on Seeking AlphaArticle d’analyse • Jan 08
There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a strong buy...Seeking Alpha • Dec 10
Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
Summary Immunocore's KIMMTRAK, targeting metastatic uveal melanoma, is FDA-approved and has shown significant clinical efficacy, with potential label expansions in cutaneous and adjuvant uveal melanoma. The company's ImmTAX platform develops TCR-based bispecific molecules, with ongoing trials for Tebentafusp and Brenetafusp in various cancers, showing promising early results. Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's strength and clarity. Despite recent stock declines and cautious market sentiment, future trial successes could make current prices attractive for conservative investors. Read the full article on Seeking AlphaArticle d’analyse • Oct 24
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Sep 19
Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 6.1x might make it look like a buy right...Seeking Alpha • Aug 12
Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Summary Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V. I also believe IMCR could be a viable takeover target, given its diverse IP, growing revenues, and strong financials, which could potentially attract big pharma. Despite premium valuation risks, Immunocore's financials are robust, making it a "buy" for long-term investors familiar with biotech risks. Read the full article on Seeking AlphaArticle d’analyse • Jul 24
Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$58.75 Immunocore...Article d’analyse • Jun 16
Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
To the annoyance of some shareholders, Immunocore Holdings plc ( NASDAQ:IMCR ) shares are down a considerable 28% in...Article d’analyse • May 11
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • May 11
Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders are probably feeling a little disappointed, since its shares fell...Article d’analyse • Apr 05
Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$83.30 Immunocore...Article d’analyse • Jan 22
Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Jan 21
Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Summary Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing immunotherapies for cancer, infectious, and autoimmune diseases. The company's stock is up around 80% since late October and now is solidly in mid-cap territory. The stock has gotten shout outs from Barron's and Robert W. Baird to start the new year. Are further gains ahead in 2024 for Immunocore shareholders? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Dec 18
Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Immunocore Holdings plc ( NASDAQ:IMCR ) shares have had a really impressive month, gaining 37% after a shaky period...Rendement pour les actionnaires
| IMCR | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 4.3% | -1.6% | -0.8% |
| 1Y | -3.9% | 34.4% | 27.1% |
Rendement vs Industrie: IMCR a sous-performé le secteur US Biotechs qui a rapporté 34.4 % au cours de l'année écoulée.
Rendement vs marché: IMCR a sous-performé le marché US qui a rapporté 27.1 % au cours de l'année écoulée.
Volatilité des prix
| IMCR volatility | |
|---|---|
| IMCR Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: IMCR n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de IMCR ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1999 | 524 | Bahija Jallal | www.immunocore.com |
Immunocore Holdings plc, avec ses filiales, développe et commercialise des médicaments immunomodulateurs pour les patients atteints de cancer, de maladies infectieuses et de maladies auto-immunes aux États-Unis, en Europe et dans le monde entier. La société propose KIMMTRAK pour le traitement du mélanome uvéal non résécable ou métastatique. Elle développe également des programmes d'oncologie, dont tebentafusp, qui est en essai clinique de phase 3 pour le traitement du mélanome cutané avancé et du mélanome uvéal adjuvant ; brenetafusp, qui est en essai clinique de phase 3 pour le traitement de première ligne du mélanome cutané avancé et en essai clinique de phase 1/2 pour le traitement de divers types de tumeurs ; IMC-R117C qui est en essai clinique de phase 1/2 pour le traitement de tumeurs solides avancées, telles que le cancer colorectal ; et IMC-P115C qui est en essai clinique de phase 1 pour les patients atteints de tumeurs exprimant le PRAME.
Immunocore Holdings plc Résumé des fondamentaux
| IMCR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$1.50b |
| Bénéfices(TTM) | -US$27.57m |
| Recettes(TTM) | US$412.81m |
3.7x
Ratio P/S-55.4x
Ratio P/ELe site IMCR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| IMCR compte de résultat (TTM) | |
|---|---|
| Recettes | US$412.81m |
| Coût des recettes | US$13.47m |
| Marge brute | US$399.35m |
| Autres dépenses | US$426.91m |
| Les revenus | -US$27.57m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.54 |
| Marge brute | 96.74% |
| Marge bénéficiaire nette | -6.68% |
| Ratio dettes/capitaux propres | 100.0% |
Quelles ont été les performances à long terme de IMCR?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 08:43 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Immunocore Holdings plc est couverte par 27 analystes. 15 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jack Allen | Baird |
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |